Study details
Enrolling now
A Phase 1 Trial of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
NCT IDNCT06515613ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
80
Study length
about 3.8 years
Ages
18+
Locations
13 sites in AR, CA, CO +10
About this study
Researchers are testing a new treatment called CTIM-76 to see if it's safe and effective for people with recurring ovarian cancer or other advanced solid tumors. The trial will involve giving CTIM-76 to adults who have not responded well to platinum-based treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CTIM-76
PhasePhase 1
Primary goalIncidence of Dose Limiting Toxicities (DLTs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of Dose Limiting Toxicities (DLTs), Overall response rate (ORR)
Body systems
Oncology